Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.

Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR, Grewal IS, Quigley M, Verona RI.

Cancer Immunol Res. 2017 Dec;5(12):1109-1121. doi: 10.1158/2326-6066.CIR-17-0258. Epub 2017 Nov 2.

PMID:
29097420
2.

Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression.

Rahman K, Vengrenyuk Y, Ramsey SA, Vila NR, Girgis NM, Liu J, Gusarova V, Gromada J, Weinstock A, Moore KJ, Loke P, Fisher EA.

J Clin Invest. 2017 Aug 1;127(8):2904-2915. doi: 10.1172/JCI75005. Epub 2017 Jun 26.

3.

Vitamin A mediates conversion of monocyte-derived macrophages into tissue-resident macrophages during alternative activation.

Gundra UM, Girgis NM, Gonzalez MA, San Tang M, Van Der Zande HJP, Lin JD, Ouimet M, Ma LJ, Poles J, Vozhilla N, Fisher EA, Moore KJ, Loke P.

Nat Immunol. 2017 Jun;18(6):642-653. doi: 10.1038/ni.3734. Epub 2017 Apr 24.

4.

Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.

Nacer A, Movila A, Sohet F, Girgis NM, Gundra UM, Loke P, Daneman R, Frevert U.

PLoS Pathog. 2014 Dec 4;10(12):e1004528. doi: 10.1371/journal.ppat.1004528. eCollection 2014 Dec.

5.

miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice.

Distel E, Barrett TJ, Chung K, Girgis NM, Parathath S, Essau CC, Murphy AJ, Moore KJ, Fisher EA.

Circ Res. 2014 Oct 10;115(9):759-69. doi: 10.1161/CIRCRESAHA.115.304164. Epub 2014 Sep 8.

6.

Ly6C(high) monocytes become alternatively activated macrophages in schistosome granulomas with help from CD4+ cells.

Girgis NM, Gundra UM, Ward LN, Cabrera M, Frevert U, Loke P.

PLoS Pathog. 2014 Jun 26;10(6):e1004080. doi: 10.1371/journal.ppat.1004080. eCollection 2014 Jun.

7.

Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct.

Gundra UM, Girgis NM, Ruckerl D, Jenkins S, Ward LN, Kurtz ZD, Wiens KE, Tang MS, Basu-Roy U, Mansukhani A, Allen JE, Loke P.

Blood. 2014 May 15;123(20):e110-22. doi: 10.1182/blood-2013-08-520619. Epub 2014 Apr 2.

8.

Immune regulation during helminth infections.

Girgis NM, Gundra UM, Loke P.

PLoS Pathog. 2013;9(4):e1003250. doi: 10.1371/journal.ppat.1003250. Epub 2013 Apr 18. No abstract available.

9.

Replication and distribution of Toxoplasma gondii in the small intestine after oral infection with tissue cysts.

Gregg B, Taylor BC, John B, Tait-Wojno ED, Girgis NM, Miller N, Wagage S, Roos DS, Hunter CA.

Infect Immun. 2013 May;81(5):1635-43. doi: 10.1128/IAI.01126-12. Epub 2013 Mar 4.

10.

Upregulation of retinal dehydrogenase 2 in alternatively activated macrophages during retinoid-dependent type-2 immunity to helminth infection in mice.

Broadhurst MJ, Leung JM, Lim KC, Girgis NM, Gundra UM, Fallon PG, Premenko-Lanier M, McKerrow JH, McCune JM, Loke P.

PLoS Pathog. 2012;8(8):e1002883. doi: 10.1371/journal.ppat.1002883. Epub 2012 Aug 23.

11.

Elucidating the role of the complement control protein in monkeypox pathogenicity.

Hudson PN, Self J, Weiss S, Braden Z, Xiao Y, Girgis NM, Emerson G, Hughes C, Sammons SA, Isaacs SN, Damon IK, Olson VA.

PLoS One. 2012;7(4):e35086. doi: 10.1371/journal.pone.0035086. Epub 2012 Apr 9.

12.

The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Girgis NM, Dehaven BC, Xiao Y, Alexander E, Viner KM, Isaacs SN.

J Virol. 2011 Mar;85(6):2547-56. doi: 10.1128/JVI.01474-10. Epub 2010 Dec 29.

13.

Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.

Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD, Piazza GA, Boeckler FM, Abadi AH.

J Med Chem. 2011 Jan 27;54(2):495-509. doi: 10.1021/jm100842v. Epub 2010 Dec 28.

14.

Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.

DeHaven BC, Girgis NM, Xiao Y, Hudson PN, Olson VA, Damon IK, Isaacs SN.

J Virol. 2010 Nov;84(21):11245-54. doi: 10.1128/JVI.00372-10. Epub 2010 Aug 18.

15.

Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Girgis NM, Dehaven BC, Fan X, Viner KM, Shamim M, Isaacs SN.

J Virol. 2008 May;82(9):4205-14. doi: 10.1128/JVI.02426-07. Epub 2008 Feb 20.

16.

A case of primary congenital glaucoma: a diagnostic dilemma.

Girgis NM, Frantz KA.

Optometry. 2007 Apr;78(4):167-75.

PMID:
17400138

Supplemental Content

Loading ...
Support Center